Sulfated rhamnose polysaccharide(SRP)derived from Enteromorpha prolifera is a metal-ion chelating agent that could potentially be used to treat diabetes.The aim of our study was to determine the effect of a variant of...Sulfated rhamnose polysaccharide(SRP)derived from Enteromorpha prolifera is a metal-ion chelating agent that could potentially be used to treat diabetes.The aim of our study was to determine the effect of a variant of SRP on DIABETES.First,we synthesized and characterized SRPE-3 chromium(III)[SRPE-3-Cr(III)]complex using an enzymatic method.The maximum chelation rate was 18.2%under optimal chelating conditions of pH 6.0,time 4 h,and temperature 60°C.Fourier transform infrared spectroscopy results showed important sites for Cr(III)-binding were O–H and C=O groups.We then studied the hypolipidemic effects of SRPE-3-Cr(III)on type 2 diabetes mellitus(T2DM)induced by a high-fat,high-sucrose diet(HFSD).Decreased blood glucose content,body fat ratio,serum TG,TC,LDL-C,and increased serum HDL-C were observed after treatment with SRPE-3-Cr(III).In addition,SRPE-3-Cr(III)significantly reduced leptin,resistin,and TNF-αlevels,and increased adiponectin contents relative to T2DM.Histopathology results also showed that SRPE-3-Cr(III)could alleviate the HFSD-lesioned tissues.SRPE-3-Cr(III)also improved lipid metabolism via a reduction in aspartate aminotransferase,alanine aminotransferase,fatty acid synthase,and acetyl-CoA carboxylase activities in the liver.SRPE-3-Cr(III)at low doses exhibited better lipid-lowering activities,hence,could be considered to be a novel compound to treat hyperlipidemia and also act as an anti-diabetic agent.展开更多
基金funded by the Innovation Capability Improvement Project of Shandong(2021TSGC1298)the Qingdao Science and Technology Project(2022).
文摘Sulfated rhamnose polysaccharide(SRP)derived from Enteromorpha prolifera is a metal-ion chelating agent that could potentially be used to treat diabetes.The aim of our study was to determine the effect of a variant of SRP on DIABETES.First,we synthesized and characterized SRPE-3 chromium(III)[SRPE-3-Cr(III)]complex using an enzymatic method.The maximum chelation rate was 18.2%under optimal chelating conditions of pH 6.0,time 4 h,and temperature 60°C.Fourier transform infrared spectroscopy results showed important sites for Cr(III)-binding were O–H and C=O groups.We then studied the hypolipidemic effects of SRPE-3-Cr(III)on type 2 diabetes mellitus(T2DM)induced by a high-fat,high-sucrose diet(HFSD).Decreased blood glucose content,body fat ratio,serum TG,TC,LDL-C,and increased serum HDL-C were observed after treatment with SRPE-3-Cr(III).In addition,SRPE-3-Cr(III)significantly reduced leptin,resistin,and TNF-αlevels,and increased adiponectin contents relative to T2DM.Histopathology results also showed that SRPE-3-Cr(III)could alleviate the HFSD-lesioned tissues.SRPE-3-Cr(III)also improved lipid metabolism via a reduction in aspartate aminotransferase,alanine aminotransferase,fatty acid synthase,and acetyl-CoA carboxylase activities in the liver.SRPE-3-Cr(III)at low doses exhibited better lipid-lowering activities,hence,could be considered to be a novel compound to treat hyperlipidemia and also act as an anti-diabetic agent.
